Search

everythinglearnresearchcommunity

for

Search:↓

Methylprednisolone pulse therapy works best for recent and specific types of severe alopecia areata.

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Certain factors like allergies, nail problems, and hair loss patterns can predict how well someone with patchy hair loss will respond to skin cream treatments.

Early onset, severe types, nail changes, family history, and body hair loss worsen alopecia areata prognosis; sticking to treatment helps.

Minoxidil works better for hair regrowth if you have higher SULT1A1 enzyme activity and ATP concentration.

Certain scalp tissue features can predict how well alopecia areata responds to steroid injections.

Alopecia areata is unpredictable, with limited treatment effectiveness, especially in severe cases.

Some treatments for folliculitis decalvans work well, with tetracyclines and a mix of rifampicin and clindamycin being most effective.

Higher IL-17A levels indicate more severe alopecia areata.

Most people in Turkey start getting gray hair around 33 years old, with factors like age, education, hair loss, skin type, family history, and anxiety playing a role.

Different treatments are effective for hair loss conditions, but results vary by individual factors.

Guidelines help design better trials to compare alopecia areata treatments.

Megavoltage radiation therapy extended survival in rabbits with thymomas, especially in those weighing more than 1.57 kg.

Half of people with Alopecia Areata may see hair regrowth within a year without treatment, but recovery is unpredictable.

Alopecia areata mainly affects young people and has significant psychological impacts, especially in males.

Pulse steroid therapy for alopecia areata shows a 43% complete response rate but has a high relapse rate, especially in children.

Careful patient selection is key for effective pulse corticosteroid treatment in children with alopecia areata.

Squaric acid dibutylester effectively treats alopecia areata.

Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.

A woman with a rare type of dermatomyositis improved with low-dose prednisone and methotrexate.

Two women were diagnosed with a rare melanoma that looked like hair loss but was actually a type of skin cancer.

Both concentrations of triamcinolone acetonide are effective for hair regrowth in patchy alopecia areata, but 5 mg/mL is recommended to reduce side effects.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.

The document concludes that different patterns of hair thickness and scalp changes can help diagnose types of non-scarring hair loss.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

Alopecia areata is a hair loss condition that often starts before age 30 and can affect various body parts, with unpredictable hair regrowth chances.

Simvastatin/ezetimibe may help some patients with severe alopecia areata regrow hair.

Melanoma survival rates vary by state and are better where incomes are higher, more people have health insurance and education, and there are more dermatologists.

Younger patients and those with more hair loss are less likely to benefit from oral steroid treatment for hair loss, and low vitamin D may predict relapse.